Vaccine Insights, Journal Year: 2023, Volume and Issue: 02(08), P. 309 - 316
Published: Aug. 23, 2023
Fast and effective testing is a critical part of pandemic preparedness response; however, during the COVID-19 pandemic, there have been major disparities in access to diagnostic tests.Here, we outline barriers progress toward equitable diagnostics highlight important lessons learned for future.
Language: Английский
Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 690 - 690
Published: March 17, 2023
This Review initiates a wide-ranging discussion over 2023 by selecting and exploring core themes to be investigated more deeply in papers submitted the Vaccines Special Issue on “Future of Epidemic Pandemic Serve Global Public Health Needs”. To tackle SARS-CoV-2 pandemic, an acceleration vaccine development across different technology platforms resulted emergency use authorization multiple vaccines less than year. Despite this record speed, many limitations surfaced including unequal access products technologies, regulatory hurdles, restrictions flow intellectual property needed develop manufacture vaccines, clinical trials challenges, that did not curtail or prevent transmission, unsustainable strategies for dealing with variants, distorted allocation funding favour dominant companies affluent countries. Key future epidemic pandemic responses will sustainable, global-public-health-driven manufacturing based equitable platform decentralised localised innovation, developers manufacturers, especially low- middle-income countries (LMICs). There is talk flexible, modular preparedness, pools non-exclusive global licensing agreements exchange fair compensation, WHO-supported transfer hubs spokes, creation prototypes ready phase I/II trials, etc. However, all these concepts face extraordinary challenges shaped current commercial incentives, unwillingness pharmaceutical governments share know-how, precariousness building capacity solely COVID-19 focus large-scale rather small-scale rapid-response innovation stop outbreaks when where they occur, inability resource-limited afford next-generation their national programmes. Once high subsidies are gone interest has waned, sustaining capability interpandemic periods require capabilities regions world just “pandemic vaccines”. philanthropic investments need leverage enforceable commitments critical so everywhere can establish scale up capability. only happen if we question prior assumptions learn lessons offered pandemic. We invite submissions special issue, which hope help guide towards research, development, ecosystem better balances integrates scientific, trial, regulatory, interests puts public health needs first.
Language: Английский
Citations
33
The Lancet, Journal Year: 2023, Volume and Issue: 401(10381), P. 978 - 982
Published: March 1, 2023
Language: Английский
Citations
28
BMJ, Journal Year: 2023, Volume and Issue: unknown, P. p413 - p413
Published: March 1, 2023
Citations
23
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(7), P. e463 - e471
Published: Jan. 4, 2024
Language: Английский
Citations
11
BMJ Global Health, Journal Year: 2024, Volume and Issue: 9(1), P. e013680 - e013680
Published: Jan. 1, 2024
COVID-19, which killed more than 6 million people, will not be the last pandemic. Vaccines are key to preventing and ending pandemics. Therefore, it is critical move now, before next pandemic, towards global vaccine equity with shared goals, intermediate steps long-term advocacy goals. Scientific integrity, ethical development, transparency, accountability communication critical. Countries can draw on lessons learnt from their response HIV pandemics, has been at vanguard of ensuring equitable access rights-based services, create goals engage communities increase delivery safe, quality vaccines. Access increased by: fostering spread mRNA intellectual property (IP) rights, manufacturing continents; creating price transparency for vaccines; easily understandable, accessible transparent data demand a new international legal framework that allows IP rights waived quickly once pandemic identified; drawing scientific expertise around world. Delivery improved strong public health systems deliver vaccines through lifespan; or strengthening national regulatory agencies independent advisory committees disseminating information reliable, subnational surveillance systems; improving understanding as become available, this may result in changes guidance; prioritising based criteria during an epidemic; developing strategies vaccinate those highest risk available
Language: Английский
Citations
8
The Lancet Global Health, Journal Year: 2023, Volume and Issue: 11(10), P. e1658 - e1666
Published: Aug. 28, 2023
Pandemic preparedness and response have relied primarily on market dynamics to drive development availability of new health products. Building calls for transformation, we propose a value proposition that instead prioritises equity from the research (R&D) stage strengthens capacity control outbreaks when where they occur. Key elements include regional R&D hubs free adapt well established technology platforms, independent clinical trials networks working with researchers, regulators, authorities better study questions comparative benefit real-world efficacy. Realising these changes requires shift in emphasis: pandemic outbreak control, one-size-fits-all economies scale manufacture local need, de novo product last-mile innovation through adaptation existing technologies, proprietary, competitive open science financing common good supports collective management sharing know-how.
Language: Английский
Citations
20
European Journal of General Practice, Journal Year: 2024, Volume and Issue: 30(1)
Published: Feb. 1, 2024
Often described as a natural economic trend, the prices that pharmaceutical companies charge for new medicines have skyrocketed in recent years. Companies claim these are justified because of 'value' treatments represent or they reflect high costs and risks associated with research development process. They also revenues generated through required to pay continued innovation.
Language: Английский
Citations
3
Bulletin of the World Health Organization, Journal Year: 2024, Volume and Issue: 102(5), P. 314 - 322
Published: May 1, 2024
Objective To obtain insights into reducing the shortfall in financing for pandemic preparedness and response measures, risk of another with social economic costs comparable to those coronavirus disease.Methods We conducted a systematic scoping review using databases ScienceDirect, Scopus, JSTOR, PubMed® EconLit.We included articles published any language until 1 August 2023, excluded grey literature publications on epidemics.We categorized eligible studies according elements framework proposed by World Health Organization Council Economy All: (i) root/structural causes; (ii) position/foundations; (iii) infrastructure systems; (iv) communities, households individuals.Findings Of 188 initially identified articles, we 60 our review.Most (53/60) were after 2020, when academic interest had shifted towards global mechanisms.Most (37/60) addressed two or more council elements.The most frequently element was systems (54/60), discussing topics such as health systems, financial markets innovation ecosystems.The roots/structural causes discussed 25 articles; individuals 22 positions/foundations 11.Conclusion Our three important gaps: formal definition response, impeding accurate quantification shortfall; research extent which has been targeted at vulnerable households; an analysis specific instruments evaluation feasibility their implementation.
Language: Английский
Citations
3
Bulletin of the World Health Organization, Journal Year: 2024, Volume and Issue: 102(5), P. 344 - 351
Published: May 1, 2024
The World Health Organization (WHO) set up the messenger ribonucleic acid (mRNA) technology transfer programme in June 2021 with a development hub South Africa and 15 partner vaccine producers middle-income countries.The goal was to support sustainable of access life-saving vaccines for people these countries as means enhance epidemic preparedness global public health.This initiative aims build resilience strengthen local research, manufacturing capacity different regions world, especially those areas that could not coronavirus disease 2019 (COVID-19) timely way.This paper outlines current market summarizes findings case study on mRNA conducted from November 2022 May 2023.The guided by vision WHO Council Economics All an economy health using its four work streams value, finance, innovation capacity.Based study, we offer mission-oriented policy framework pilot transformative change towards ecosystem common good.Parts this have already been incorporated into governance programme, while other aspects, good approach, still need be applied achieve goals programme.
Language: Английский
Citations
3
BMJ Global Health, Journal Year: 2023, Volume and Issue: 8(6), P. e012636 - e012636
Published: June 1, 2023
Language: Английский
Citations
8